Sentence: In newly diagnosed patients with MCL ineligible for intensive therapy and ASCT , the standard-of-care has generally been R-CHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine , and prednisone ) , followed by rituximab , maintenance .
Drug combination annotation:
[{'class': 'POS', 'spans': ['rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone', 'rituximab'], 'is_context_needed': False}]